About Pacira Biosciences, Inc. 
Pacira Biosciences, Inc.
Pharmaceuticals & Biotechnology
Pacira BioSciences, Inc., formerly Pacira Pharmaceuticals, Inc. is a holding company. The Company is a pharmaceutical company focused on the development, manufacture and commercialization of pharmaceutical products, based on its DepoFoam extended release drug delivery technology, for use primarily in hospitals and ambulatory surgery centers. Its lead product candidate is EXPAREL (bupivacaine liposome injectable suspension), which consists of bupivacaine, an amide-type local anesthetic, encapsulated in DepoFoam and is indicated for single-dose infiltration into the surgical site to produce postsurgical analgesia. In addition to EXPAREL, DepoFoam is also the basis for its other Food and Drug Administration-approved commercial product, DepoCyt(e), which it manufactures for its commercial partners, as well as its product candidates. The Company's other product candidates include DepoMeloxicam (DepoMLX) and DepoTranexamic Acid (DepoTXA).
Company Coordinates 
Company Details
5 Sylvan Way Ste 300 , PARSIPPANY NJ : 07054-3813
Registrar Details
Shareholding Snapshot
Shareholding Compare (%holding) 
Majority shareholders
Domestic Funds
Domestic Funds
Held in 96 Schemes (62.02%)
Foreign Institutions
Held by 123 Foreign Institutions (14.53%)
Strategic Entities with highest holding
Highest Public shareholder
Management
Designation
Mr. David Stack
Chairman of the Board, Chief Executive Officer
Mr. Paul Hastings
Lead Independent Director
Gov. Christopher Christie
Director
Ms. Laura Brege
Independent Director
Dr. Mark Froimson
Independent Director
Dr. Yvonne Greenstreet
Independent Director
Revenue and Profits:
Net Sales:
181 Million
(Quarterly Results - Jun 2025)
Net Profit:
-5 Million
Pharmaceuticals & Biotechnology
USD 1,202 Million (Small Cap)
19.00
NA
0.00%
0.19
5.05%
1.59






